CD95 is a cell surface receptor involved in
apoptotic signal transmission. Deregulation of this pathway results in down
regulation of apoptosis and subsequent persistence of a malignant clone. A
single nucleotide polymorphism (SNP) resulting in guanine-to-adenine (G > A)
transition in the CD95 promoter region (position ﹣1377) is thought to reduce
stimulatory protein 1 (SP1) transcription factor binding and decrease CD95
expression. The purpose of this study was to examine a genetic polymorphism in
the core promoter of CD95 is associated with the frequency. G-1377A in the CD95
promoter region was genotyped by polymerase chain reaction and restriction
endonuclease analysis and sequenced of the CD95 gene (Beckman Coulter, USA). Among 146 patients, CD95 G-1377A (rs2234767) SNP
carriers frequencies has been identified as 25% GA (n:37) and AA 4% (n:6),
respectively. This polymorphism of the distribution of the CD95 gene in acute
leukemic children will be a guide for future studies.
Cite this paper
Bali, D. F. A. , Ozkan, D. T. , Kurekci, A. E. and Akar, N. (2018). Screening of Single Nucleotide Polymorphism in CD95 (APO-1/FAS) Promoter Region (G-1377A) in Children with Acute Leukemia. Open Access Library Journal, 5, e4385. doi: http://dx.doi.org/10.4236/oalib.1104385.
Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., Trauth, B.C., et al. (1992) Purification and Molecular Cloning of the APO-1 Cell Surface Antigen, a Member of the Tumor Necrosis Factor/Nerve Growth Factor Receptor Superfamily. Sequence Identity with the Fas Antigen. Journal of Biological Chemistry, 267, 10709-10715.
Leithauser, F., Dhein, J. and Mechtersheimer, G. (1993) Constitutive and Induced Expression of APO-1, a New Member of the Nerve Growth Factor/Tumor Necrosis Factor Receptor Superfamily, in Normal and Neoplastic Cells. Laboratory Investigation, 69, 415-429.
Watanabe-Fukunaga, R., Brannan, C.I., Copeland, N.G., Jenkins, N.A. and Nagata, S. (1992) Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen That Mediates Apoptosis. Nature, 356, 314-317. https://doi.org/10.1038/356314a0
Rieux-Laucat, F., Le Deist, F., Hivroz, C., Roberts, I.A., Debatin, K.M., Fischer, A. and de Villartay, J.P. (1995). Mutations in Fas Associated with Human Lymphoproliferative Syndrome and Autoimmunity. Science, 268, 1347-1349. https://doi.org/10.1126/science.7539157
Owen-Schaub, L.B., Meterission, S. and Ford, R.J. (1993) Fas/APO-1 Expression and Function on Malignant Cells of Hematologic and Non-Hematologic Origin. Journal of Immunotherapy, 14, 234-241. https://doi.org/10.1097/00002371-199310000-00011
Hu, Z., Li, C., Chen, K., Wang, L.E., Sturgis, E.M., Spitz, M.R. and Wei, Q. (2008) Single Nucleotide Polymorphisms in Selected Apoptotic Genes and BPDE-Induced Apoptotic Capacity in Apparently Normal Primary Lymphocytes: A Genotype-Phenotype Correla-tion Analysis. Journal of Cancer Epidemiology, 2008, Article ID: 147905. https://doi.org/10.1155/2008/147905
Baryshnikov, A., Polosukhina, E.R. and Tupitsin N.N. (1999) CD95 (FAS/APO-1) Antigen Is a New Prognostic Marker of Blast Cells of Acute Lymphoblastic Leukaemia Patients. Advances in Experimental Medicine and Biology, 457, 251-258. https://doi.org/10.1007/978-1-4615-4811-9_27
Aref, S., Salama, O. and Al-Tonbary. Y. (2004) Assessment of Bcl-2 Expression as Modulator of Fas Mediated Apoptosis in Acute Leukemia. Hematology, 9, 113-121. https://doi.org/10.1080/1024533042000205496
Wuchter, C., Karawajew, L. and Ruppert, V. (1999) Clinical Significance of CD95, Bcl-2 and Bax Expression and CD95 Function in Adult de Novo Acute Myeloid Leukemia in Context of P-Glycoprotein Function, Maturation Stage, and Cytogenetics. Leukemia, 13, 1943-1953. https://doi.org/10.1038/sj.leu.2401605
Wuchter, C., Karawajew, L. and Ruppert, V. (2000) Constitutive Expression Levels of CD95 and Bcl-2 as Well as CD95 Function and Spontaneous Apoptosis in Vitro Do Not Predict the Response to Induction Chemotherapy and Relapse Rate in Childhood Acute Lymphoblastic Leukaemia. British Journal of Haematology, 110, 154-160. https://doi.org/10.1046/j.1365-2141.2000.02147.x